Company: MDXG
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001376339-25-000009
Chunk: 104

Company: MIMEDX GROUP, INC.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1A
Chunk 104
---
 to serve on our board as directors. The interests of EW Healthcare Partners may conflict with those of our other shareholders, and EW Healthcare Partners may seek to influence, and may be able to influence, us through its director nomination rights and its share ownership.

The price of our Common Stock has been, and will likely continue to be, volatile.

The market price of our Common Stock, like that of the securities of many other healthcare companies that are engaged in research, development, and commercialization, has fluctuated over a wide range, and it is likely that the price of our Common Stock will fluctuate in the future. The market price of our Common Stock could be impacted by a variety of factors, including:

•Fluctuations in stock market prices and trading volumes of similar companies or of the markets generally;

•Our ability to successfully launch, market and earn significant revenue from our products;

•Our ability to obtain additional financing to support our continuing operations;

•Disclosure of the details and results of our clinical trials and our regulatory applications and proceedings;

•Developments in and disclosure or publicity regarding existing or new litigation or contingent liabilities;

•Changes in government regulations or our failure to comply with any such regulations;

•Additions or departures of key personnel;

•Our investments in research and development or other corporate resources;

•Announcements of technological innovations or new commercial products by us or our competitors;

•Developments in the patents or other proprietary rights owned or licensed by us or our competitors;

•The timing of new product introductions;

•Actual or anticipated fluctuations in our operating results, including as a result of seasonality in our business, as well as any restatements of previously reported results;

•Our ability to effectively and consistently process or manufacture our products and avoid costs associated with the recall of defective or potentially defective products;

•Our ability and the ability of our distribution partners to market and sell our products;

•Changes in reimbursement for our products or the price for our products to our customers;

•Removal of our products from the FSS, or changes in how government accounts purchase products such as ours or in the price for our products to government accounts;

•Activities of market participants and investors, including analysts and MIMEDX shareholders;

•Material amounts of short-selling of our Common Stock; and

•The other risks detailed in this Item 1A.

34

Any unanticipated shortfall in our revenue in any fiscal quarter could have an adverse effect on our results of operations in that quarter. The effect on our net income of such a shortfall